The combination of Nivolumab with the Ipilimumab, an anti-CTLA4 monoclonal antibody, has been authorized in 2019 for the first-line treatment of RCC in patients who were not previously treated, at moderate or at high risk of worsening. Here, CTLA4 is linked to renal cell carcinoma.